Summary: Acute Attacks

2015 ◽  
pp. 282-284
Author(s):  
J. G. Widdicombe
Keyword(s):  
Acute Attacks

ДОЛГОСРОЧНАЯ ПРОФИЛАКТИКА АНГИООТЕКОВ У ПАЦИЕНТОВ С НАО

2019 ◽  
pp. 75-83
Author(s):  
T.V. Latysheva ◽  
E.A. Latysheva ◽  
I.A. Manto
Keyword(s):  
Depressive Disorders ◽  
Daily Life ◽  
Social Activity ◽  
Psychological Impact ◽  
Therapeutic Strategies ◽  
Risk Of Death ◽  
Career Opportunities ◽  
Acute Attacks ◽  
Life Career

Наследственный ангиоотек (НАО) с дефицитом С1ингибитора (С1ИНГ) представляет собой редкое заболевание, которое оказывает сильное воздействие на жизнь пациентов как физически, так и эмоционально. Непредсказуемость атак влияет на повседневную жизнь, выбор профессии, социальную активность. Кроме того, страх перед развитием отека, а также связанными с ним болью и риском смерти приводит к депрессивным расстройствам, характерным для хронических, в особенности жизнеугрожающих заболеваний. Появление современных патогенетических препаратов способно минимизировать влияние НАО и улучшить качество жизни больных. В основе терапии НАО лежат долгосрочная профилактика, краткосрочная профилактика и купирование острых атак. В данной статье речь пойдет о долгосрочной профилактике.Hereditary angioedema (HAE) due to of C1inhibitor deficiency is a rare disease, which causes a strong physical and psychological impact on patients lives. HAE affects daily life, career opportunities, and social activity. In addition, fear of the edema development, as well as the associated with it pain and risk of death leads to depressive disorders specific for chronic (especially lifethreatening) diseases. The emergence of modern pathogenetic drugs can minimize the effect of HAE and improve the patients quality of life. There are three different therapeutic strategies that are used for HAE treatment: longterm prophylaxis, shortterm and ondemand therapy for acute attacks. This article focuses on longterm prophylaxis.

scholarly journals COVID‐19 as a trigger of acute attacks in people with hereditary angioedema

2021 ◽  
Author(s):  
Aude Belbézier ◽  
Mélanie Arnaud ◽  
Isabelle Boccon‐Gibod ◽  
Fabien Pelletier ◽  
Chloé McAvoy ◽  
...  
Keyword(s):  
Hereditary Angioedema ◽  
Acute Attacks

scholarly journals Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management

2020 ◽  
Vol 68 (8) ◽  
pp. 1309-1316
Author(s):  
Mahesh Gajendran ◽  
Joshua Sifuentes ◽  
Mohammad Bashashati ◽  
Richard McCallum
Keyword(s):  
Symptom Control ◽  
Well Being ◽  
Clinical Entity ◽  
Cyclic Vomiting Syndrome ◽  
Cannabinoid Hyperemesis Syndrome ◽  
Acute Attacks ◽  
Hot Baths ◽  
Term Management ◽  
Cyclic Vomiting

Although cannabinoid hyperemesis syndrome (CHS) was first reported more than 15 years ago, it still remains an unfamiliar clinical entity among physicians worldwide. CHS is categorized by Rome IV classification as a functional gastroduodenal disorder. It is characterized by stereotypical episodic vomiting in the setting of chronic, daily cannabis use, with cycles decreasing by the cessation of cannabis. CHS is also associated with abdominal pain reduced by hot baths and showers with comparative well-being between attacks. Thus, its clinical presentation resembles ‘classic’ cyclic vomiting syndrome, but eliciting a cannabis history is crucial in diagnosing this entity. In acute attacks, parenteral benzodiazepines are very effective. For prevention and long-term management, tricyclic antidepressants such as amitriptyline are the mainstay of therapy requiring doses in the range of 50–200 mg/d to achieve symptom control. In addition, counseling to achieve marijuana cessation, accompanied by antianxiety medications, is necessary for sustaining clinical outcomes. Once the patient is in remission and off marijuana for a period of 6–12 months, then tapering the dose of amitriptyline can be implemented, with the goal of no therapy being achieved in the majority of patients over time. With the legalization of marijuana in many states, CHS will become an increasingly prevalent clinical entity, so educating about CHS is an important goal, particularly for emergency department physicians who generally first encounter these patients.

Antibacterial Therapy and Middle Ear Effusions

1976 ◽  
Vol 85 (2_suppl) ◽  
pp. 250-253 ◽  
Author(s):  
Paul A. Shurin
Keyword(s):  
Drug Therapy ◽  
Effective Treatment ◽  
Otitis Media ◽  
Middle Ear ◽  
Middle Ear Effusion ◽  
Prolonged Administration ◽  
Antimicrobial Drugs ◽  
Acute Attacks ◽  
Ear Effusion

Antimicrobial drugs chosen for their activity against the causative pathogens of otitis media provide effective treatment for acute attacks. Prolonged administration of some of these agents has recently been shown to be of value in the prevention of symptomatic otitis. The role of drug therapy in the management of chronic or recurrent middle ear effusion is unknown at present.

To the treatment of bronchial asthma

1936 ◽  
Vol 32 (8) ◽  
pp. 928-932
Author(s):  
L. B. Shalman
Keyword(s):  
Bronchial Asthma ◽  
Acute Attacks

The treatment of acute attacks of bronchial asthma is currently not controversial.

Correction: drugs in the hereditary hepatic porphyrias (2 July, p. 56)

1976 ◽  
Vol 14 (18) ◽  
pp. 72-72
Keyword(s):  
Enzyme Inducer ◽  
Acute Attacks

In this article we did not mention rifampicin which, although it has not been implicated as a cause of acute attacks of porphyria, is a powerful enzyme inducer and should not be given to these patients.

A Treatment for the Acute Migraine Attack

1987 ◽  
Vol 15 (2) ◽  
pp. 71-75 ◽  
Author(s):  
E. I. Adam
Keyword(s):  
Acute Attack ◽  
Response To Treatment ◽  
Codeine Phosphate ◽  
Double Blind ◽  
Recent Onset ◽  
Randomized Crossover Trial ◽  
History Of ◽  
Specific Factors ◽  
Acute Attacks ◽  
Acute Migraine Attack

A compound analgesic/anti-emetic formulation was significantly effective in reducing the severity of acute attacks of migraine, in a double-blind, randomized, crossover trial of 34 patients referred to a migraine clinic. The preparation contained paracetamol (acetaminophen) 500 mg, codeine phosphate 8 mg, buclizine hydrochloride 6.25 mg and dioctyl sodium sulphosuccinate 10 mg. The dosage was two tablets taken as early as possible in the acute attack. No specific factors could be identified which influenced response to treatment Patients with a long history of migraine (more than 10 years) responded as well as those with a recent onset of the condition.

Sign in / Sign up

Export Citation Format

Share Document